Lyra Therapeutics Newsroom

BTIG Initiates Lyra Therapeutics(LYRA.US) With Hold Rating

Moomoo NewsMay 8 12:31 ET

Analysts Offer Insights on Healthcare Companies: Inogen (INGN) and Lyra Therapeutics (LYRA)

TipRanksMay 8 06:12 ET

BTIG Keeps Their Hold Rating on Lyra Therapeutics (LYRA)

TipRanksMay 8 06:12 ET

William Blair Initiates Lyra Therapeutics(LYRA.US) With Hold Rating

Moomoo NewsMar 14 12:32 ET

Analysts Have Conflicting Sentiments on These Healthcare Companies: Arcus Biosciences (RCUS), ATyr Pharma (ATYR) and Lyra Therapeutics (LYRA)

TipRanksMar 14 07:05 ET

Lyra Therapeutics Analyst Ratings

BenzingaMar 14 06:54 ET

Lyra Therapeutics: Hold Rating Due to Uncertainty in ENLIGHTEN-2 Trial Outcomes

TipRanksNov 14, 2024 06:19 ET

BTIG Maintains Lyra Therapeutics(LYRA.US) With Hold Rating

Moomoo NewsNov 13, 2024 06:36 ET

HC Wainwright & Co. Reiterates Neutral on Lyra Therapeutics, Maintains $2 Price Target

BenzingaAug 15, 2024 07:05 ET

Lyra Therapeutics Analyst Ratings

BenzingaAug 15, 2024 07:02 ET

BTIG Maintains Lyra Therapeutics(LYRA.US) With Hold Rating

Moomoo NewsAug 15, 2024 06:31 ET

Lyra Therapeutics Analyst Ratings

BenzingaJun 20, 2024 13:40 ET

Jefferies Cuts Lyra to Hold in Wake of Failed Phase 3 Study

Seeking AlphaMay 7, 2024 11:14 ET

Jefferies Downgrades Lyra Therapeutics to Hold, Price Target at $0.50

MT NewswiresMay 7, 2024 07:41 ET

Analysts Offer Insights on Healthcare Companies: Lyra Therapeutics (LYRA), Bristol-Myers Squibb (BMY) and Axsome Therapeutics (AXSM)

TipRanksMay 7, 2024 05:25 ET

Sell Rating on Lyra Therapeutics Amid Phase 3 Study Failure and Funding Concerns

TipRanksMay 7, 2024 05:21 ET

BTIG Downgrades Lyra Therapeutics (LYRA) to a Hold

TipRanksMay 6, 2024 11:00 ET

Buy Rating Affirmed for Lyra Therapeutics Amid Strong Phase 3 Prospects for LYR-210

TipRanksMay 2, 2024 08:26 ET

Lyra Therapeutics Analyst Ratings

BenzingaMay 1, 2024 06:33 ET

Buy Rating for Lyra Therapeutics Backed by Upcoming Catalysts and Market Potential

TipRanksMay 1, 2024 06:21 ET